The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 353:1180-1181 September 15, 2005 Number 11
NextNext

Antibody to {alpha}4{beta}7 Integrin for Ulcerative Colitis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Feagan, B. G.
-PubMed Citation
To the Editor: The {alpha}4{beta}7 integrin plays a crucial role in the physiological homing of T cells and monocytes by mediating specific binding of these cells to mucosal addressin-cell adhesion molecule 1 (MAdCAM-1) and vascular-cell adhesion molecule 1 (VCAM-1) on the intestinal microvasculature.1 Feagan et al. (June 16 issue)2 report efficacy in the treatment of ulcerative colitis with MLN02, a humanized antibody that blocks the {alpha}4{beta}7 integrin. However, a similar drug that interrupted leukocyte homing through blockade of the {alpha}4{beta}1 integrin (natalizumab) has recently caught the attention of clinical investigators in inflammatory bowel disease. Natalizumab reduced immune surveillance in the brain — an . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.